Utilization of Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Juvenile Idiopathic Arthritis

Abstract

A227treatments; a tendency to lower values was observed with Tocilizumab. At the time of the last evaluation 56% of patients were in remission, 21% had mild activity, 19% had moderate activity and 5% severe activity. All patients with severe activity suspended treatment, and 16% of patients with moderate activity did. Average treatment time 3.7 years. ConClusions: Treatment of RA with biological therapy in CCSS has been effective in a majority of patients, without differences between therapies with a tendency to better response with Tocilizumab that should be evaluated in a future.